Clinical trial could help patients at risk of hidden cardiovascular leg disease
Credit: Peopleimages.com – YuriArcurs
A medication commonly used to treat gout could be the key to reducing a cardiovascular condition that puts one in five people aged over 75 at risk of devastating complications like leg ulcers, gangrene and amputation.
Monash University and Eastern Health are examining the use of the anti-inflammatory drug Colchicine to prevent peripheral artery disease (PAD) as part of the international LEADER-PAD clinical trial.
PAD occurs when the arteries that deliver blood to the legs narrow as a result of atherosclerosis, a chronic condition that blocks arteries.
A key contributor to the condition is inflammation, so it is hoped that Colchicine could result in better outcomes for PAD patients.
Associate Professor Anthony Dear from Eastern Health Clinical School is overseeing the trial in Melbourne patients and hopes it will drastically improve their quality of life.
“Colchicine is cheap, safe, orally available and can be used long term, so it has all the hallmarks of a drug that could be of significant benefit, not only in developed countries but also in developing countries as a way of preventing this devastating disease,” Associate Professor Dear said.
“We know that even with medical and surgical interventions, PAD patients have an elevated risk of poor cardiovascular outcomes that can reduce their mobility and independence.
“If it proves effective, this is a treatment option that could be life-changing for those who would otherwise be risking outcomes as severe as amputation.”
As a result of under-research and poor public promotion, PAD often goes undiagnosed until it’s too late.
Associate Professor Dear said this has startlingly resulted in up to 30 per cent of PAD patients dying within five years of developing the condition.
“Historically, there has been a lack of clinical trials and funding focused on PAD patients themselves,” he said.
“Presentation is often not as dramatic as heart attacks or stroke in coronary artery disease or cerebrovascular disease.
“In fact, it’s often referred to as the Cinderella of cardiovascular disease; it’s hidden and doesn’t get the attention it desperately needs.”
The LEADER-PAD trial, originating in Canada, is a randomised, placebo-controlled trial looking at the effects of a low dose of Colchicine on cardiovascular outcomes in PAD patients.
It involves around 6000 patients across the world, 1000 of which are anticipated in Australia.
About Monash University
Monash University is Australia’s largest university with more than 80,000 students. In the 60 years since its foundation, it has developed a reputation for world-leading high-impact research, quality teaching, and inspiring innovation.
With four campuses in Australia and a presence in Malaysia, China, India, Indonesia and Italy, it is one of the most internationalised Australian universities.
As a leading international medical research university with the largest medical faculty in Australia and integration with leading Australian teaching hospitals, we consistently rank in the top 50 universities worldwide for clinical, pre-clinical and health sciences.
For more news, visit Medicine, Nursing and Health Sciences or Monash University.
MEDIA ENQUIRIES